Angiotensin-converting enzyme inhibitors.

@article{Brown1998AngiotensinconvertingEI,
  title={Angiotensin-converting enzyme inhibitors.},
  author={Nancy J. Brown and Douglas E. Vaughan},
  journal={Circulation},
  year={1998},
  volume={97 14},
  pages={
          1411-20
        }
}
ACE inhibitors have achieved widespread usage in the treatment of cardiovascular and renal disease. ACE inhibitors alter the balance between the vasoconstrictive, salt-retentive, and hypertrophic properties of angiotensin II (Ang II) and the vasodilatory and natriuretic properties of bradykinin and alter the metabolism of a number of other vasoactive substances. ACE inhibitors differ in the chemical structure of their active moieties, in potency, in bioavailability, in plasma half-life, in… Expand

Paper Mentions

Observational Clinical Trial
As a third-generation dihydropyridine calcium channel blocker (CCB), Amlodipine is mainly used in a single therapy or combined therapy for hypertension or angina. Edema, one of… Expand
ConditionsEssential Hypertension
InterventionDrug
Reinventing the ACE inhibitors: some old and new implications of ACE inhibition
TLDR
Since their inception, angiotensin-converting enzyme (ACE) inhibitors have been used as first-line therapy for the treatment of cardiovascular and renal diseases and elucidated protective roles for them in both memory-related disorders and cancer. Expand
Pharmacological review on Natural ACE inhibitors
TLDR
This review focuses on phytochemicals, chemistry, mechanism, and lead compounds derived from plants and use to control or in the treatment of hypertension. Expand
ACE Inhibitors: Pharmacology
TLDR
ACE inhibitors not only lower blood pressure but also positively influence a number of cardiovascular risk factors such as cardiac and vascular hypertrophy, endothelial dysfunction, atherosclerosis or insulin resistance. Expand
Chapter 28 Mode of action of angiotensin converting enzyme inhibitors
TLDR
In essential hypertension, ACE inhibitors are at least as effective as other agents in lowering blood pressure and the results of long term clinical trials currently underway will determine whether this translates into a reduction in cardiovascular morbidity and mortality. Expand
Evolution of angiotensin-converting enzyme inhibition in hypertension, heart failure, and vascular protection.
  • W. Parmley
  • Medicine
  • The American journal of medicine
  • 1998
TLDR
Initial research indicates a reversal of endothelial dysfunction in atherosclerotic animals, and subsequent clinical trials, including the Trial on Reversing ENdothelial Dysfunction (TREND), support the likelihood of a similar effect in humans. Expand
The use of ACE inhibitor in cardiovascular disease.
TLDR
Advantages of its therapeutic use, the adverse effects that might occur as well as how to overcome this effect and also when it should be stopped are discussed. Expand
Impact of kinins in the treatment of cardiovascular diseases.
TLDR
How and why imbalances created by overactive RAS are best corrected by treatments with ACEI or AT1-RAs are discussed. Expand
Angiotensin converting enzyme (ACE) inhibitory peptides: production and implementation of functional food.
TLDR
This review focuses on the use, application and future perspective of bioactive peptides with properties relevant to cardiovascular health, including ACE inhibitory peptides derived from plant and animal proteins. Expand
New horizons for stroke prevention: PROGRESS and HOPE
TLDR
The epidemiological evidence for hypertension as a risk factor for stroke, a national guideline for blood-pressure control to reduce the incidence of stroke and cardiovascular disease, and the findings of the PROGRESS and HOPE trials are explored, showing that ACE inhibitors have an important role in the prevention of strokes and cardiovascular-disease events. Expand
Angiotensin-converting enzyme inhibition: a landmark advance in treatment for cardiovascular diseases
TLDR
Accumulating clinical data is such that guidelines developed for cardiologists by professional societies now recommend the use of ACE inhibitors for the management of HT, coronary and atherosclerotic vascular disease, MI, and HF. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 211 REFERENCES
Differential effects of angiotensin converting enzyme inhibitors on the vasodepressor and prostacyclin responses to bradykinin.
TLDR
Comparing the effects of captopril, quinapril and placebo on blood pressure, urinary excretion of 2,3-dinor-6-keto-PGF1 alpha, and the vasodepressor response to i.v. bradykinin suggests that although ACE inhibitors increase prostaglandins by increasing brady Kinin, ACE inhibitors may attenuate prostag landin production through a second bradyKinin-independent mechanism. Expand
Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors.
TLDR
The effect of ACE inhibition in LVH was investigated in rats made hypertensive by aortic banding and ACE inhibition with ramipril, in the antihypertensive dose of 1 mg/kg/day for 6 weeks, prevented the increase in blood pressure and the development of LVH. Expand
Renal effects of angiotensin-converting enzyme inhibition in cardiac failure.
  • V. Dzau
  • Medicine
  • American journal of kidney diseases : the official journal of the National Kidney Foundation
  • 1987
TLDR
T titration of the ACE inhibitors' dose is recommended to minimize hypotension and the concurrent use of furosemide in patients with CHF receiving ACE inhibitors, especially for those in whom azotemia, hyponatremia, and hypokalemia complicate the course. Expand
Role of Bradykinin in Mediating Vascular Effects of Angiotensin-Converting Enzyme Inhibitors in Humans
TLDR
The vascular effects of the ACE inhibitor quinaprilat, the selective bradykinin B2-receptor antagonist icatibant, and their combination were determined at rest, during reactive hyperemia, and during sodium nitroprusside, causing endothelium-independent dilation. Expand
Adverse Reactions with Angiotensin Converting Enzyme (ACE) Inhibitors
TLDR
Enalapril (MK421) is the first of what appears to be a growing number of analogues which are structurally and pharmacodynamically different from captopril; yet, they possess the same capacity for inhibiting the activity of angiotensin converting enzyme. Expand
Oral angiotensin-converting enzyme inhibitor in long-term treatment of hypertensive patients.
TLDR
The results indicate that chronic inhibition of the angiotensin-converting enzyme with an orally active compound offers a new, efficient, and well-tolerated approach to the treatment of hypertension. Expand
Effect of angiotensin II blockade on cardiac hypertrophy and remodelling: a review.
  • B. Dahlöf
  • Medicine
  • Journal of human hypertension
  • 1995
TLDR
Taking into account the shortcomings of today's anti-hypertensive treatment to achieve normalisation of excessive cardiovascular morbidity and mortality, as well as the seemingly great importance of the renin-angiotensin system for hypertension-induced functional and structural abnormalities, a therapy based on a specific All antagonist could offer obvious advantages in a high risk hypertensive patient with cardiovascular hypertrophy. Expand
LONG-TERM EFFECTS OF CAPTOPRIL (SQ14 225) ON BLOOD-PRESSURE AND HORMONE LEVELS IN ESSENTIAL HYPERTENSION
TLDR
The hypotensive action of captopril is not mediated by changes in blood-bradykinin but may involve inhibition of the renin-angiotensin and kallikrein-kinin systems locally within the kidneys or blood vessels. Expand
Urinary excretion of prostacyclin and thromboxane A2 metabolites after angiotensin converting enzyme inhibition in hypertensive patients.
TLDR
The antihypertensive action of ACEI, alone or in combination with HCTZ, does not appear to involve alterations in these vasoactive prostaglandins. Expand
Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man.
TLDR
SQ 14225 is a promising new antihypertensive agent, effective in patients refractory to traditional medical therapy, and the exact mechanisms contributing to the blood-pressure-lowering effect of this agent remain unclear. Expand
...
1
2
3
4
5
...